Challenges With Targeted Therapies in Ovarian Cancer

Brian Burgess, DO, PhD

Brian Burgess, DO, PhD, a first-year fellow at the University of Kentucky, discusses the biggest challenge with targeted therapies in ovarian cancer. PARP resistance has become a huge barrier in this treatment paradigm. 

Brian Burgess, DO, PhD, a first-year fellow at the University of Kentucky, discusses the biggest challenge with targeted therapies in ovarian cancer. PARP resistance has become a huge barrier in this treatment paradigm.

While the drugs in this field are very potent, chemotherapy resistance presents itself as a major challenge when treating patients with ovarian cancer. Burgess says that researchers believed targeted therapies would help overcome such barriers, but chemotherapy resistance becomes an issue primarily in long-term treatment.